Abstract：
Growing evidence suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) is significantly higher in men versus women. Increased prevalence is observed in postmenopausal women, suggesting that age and sex (hormones) influence MASLD development and progression. Molecular data further reveal that sex regulates the innate immune responses with an essential role in MASLD progression. To date, there has been limited focus on the role of innate immune sexual dimorphism in MASLD, and differences between men and women are not considered in the current drug discovery landscape. In this review, we summarize the sex disparities and innate immune sexual dimorphism in MASLD pathogenesis. We further highlight the importance of harnessing sexual dimorphism in identifying therapeutic targets, developing pharmacological therapies, and designing (pre-) clinical studies for the personalized treatment for MASLD.
摘要：
越来越多的证据表明，代谢功能障碍相关的脂肪变性肝病（MASLD）在男性中明显高于女性。在绝经后妇女中观察到患病率增加，表明年龄和性别（激素）影响MASLD的发育和进展。分子数据进一步表明，性别调节先天免疫反应，在MASLD进展中起重要作用。迄今为止,对先天免疫性二态在MASLD中的作用的关注有限，在当前的药物发现环境中，没有考虑到男女之间的差异。在这次审查中,我们总结了MASLD发病机制中的性别差异和先天免疫性二态。我们进一步强调了在确定治疗目标中利用性二态性的重要性，开发药物疗法，并为MASLD的个性化治疗设计（预）临床研究。
